Market Cap (In CAD)
37.61 Million
Revenue (In CAD)
-
Net Income (In CAD)
-20.3 Million
Avg. Volume
26.77 Thousand
- Currency
- CAD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.64-8.0
- PE
- -
- EPS
- -
- Beta Value
- 1.816
- ISIN
- CA1079301091
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. William V. Williams M.D.
- Employee Count
- -
- Website
- https://www.briacell.com
- Ipo Date
- 2012-08-13
- Details
- BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
More Stocks
-
GOSSGossamer Bio, Inc.
GOSS
-
7578Revivegen Co., Ltd.
7578
-
4770Allied Supreme Corp.
4770
-
AVL
-
KMNCFKingsmen Creatives Ltd.
KMNCF
-
ASIMAR
-
ITXItaconix plc
ITX
-
0L8F